Biotech News
Related news
OTLKOutlook2026-04-22 12:30 EST
Outlook Therapeutics Announces $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
OTLKOutlook2026-04-23 20:05 EST
Outlook Therapeutics Announces Closing of $5.0 Million Registered Direct Offering
PRQRProQR Therapeutics2026-06-25 10:35 EST
ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
OCGNOcugen2026-05-04 20:01 EST
Ocugen Announces Private Offering of $115 Million of Convertible Senior Notes
TARSTarsus Pharmaceuticals2026-08-06 11:02 EST
Tarsus Pharmaceuticals Announces Oversubscribed $125.0 Million Private Placement Equity Financing
IRIXIRIDEX2026-07-20 11:00 EST
Iridex Adds EndoProbe® Handpieces to EyeProGPO Product Offering
LENZLenz Therapeutics Inc2026-07-06 12:15 EST
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
BLTEBelite Bio2026-04-27 12:00 EST
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit
LCTXLineage Cell Therapeutics2026-09-08 12:00 EST
Lineage Cell Therapeutics Announces Issuance of Patent Underlying Its AlloSCOPE™ 5D Manufacturing Platform
OCSOculis2026-08-10 07:30 EST
Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company
Outlook
Ophthalmic Bevacizumab Company Outlook Therapeutics develops and commercializes LYTENAVA, a bevacizumab formulation manufactured specifically for intravitreal administration in retinal diseases. The company is building a focused ophthalmology franchise around an approved alternative to repackaged bevacizumab originally produced for...
Recent company news
OTLKOutlook2026-09-11 11:00 EST
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
OTLKOutlook2026-09-10 13:10 EST
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
OTLKOutlook2026-08-27 20:05 EST
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
OTLKOutlook2026-08-27 13:01 EST
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
OTLKOutlook2026-08-14 11:15 EST
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Stock data
- Close
- 0.68 USD
- Market cap
- 120.89M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States